Amneal Pharmaceuticals, Inc (AMRX) FinancialsAMRXAmneal Pharmaceuticals, Inc

Amneal Pharmaceuticals, Inc (AMRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oral solid, accounting for 23.7% of total sales, equivalent to $171.10M. Other significant revenue streams include Distribution and Central Nervous System. Understanding this composition is critical for investors evaluating how AMRX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Amneal Pharmaceuticals, Inc maintains a gross margin of 42.01%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.33%, while the net margin is 8.74%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AMRX converts its operational activities into shareholder value.

In the context of the broader market, AMRX competes directly with industry leaders such as RYTM and KNSA. With a market capitalization of $6.04B, it holds a significant position in the sector. When comparing efficiency, AMRX's gross margin of 42.01% stands against RYTM's 26.52% and KNSA's 90.32%. Such benchmarking helps identify whether Amneal Pharmaceuticals, Inc is trading at a premium or discount relative to its financial performance.

Amneal has shown strong revenue growth, with total revenue reaching $814 million in Q4 2025 and $796 million in Q2 2026. The gross margin has improved significantly, reaching 44.31% in Q1 2026, indicating better cost management and profitability.